Drug Trial Radar · NCT04802057
Safety and Tolerability Study in Adults With Cold Agglutinin Disease Previously Treated With SAR445088 or Never Treated With SAR445088
Last checked: Nov 19, 2026Latest source record: Sep 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
9
Actual
Start
Mar 22, 2021
Primary completion
Mar 4, 2025
Study completion Mar 4, 2025
Sponsor
- Lead sponsor
- Bioverativ, a Sanofi companySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Mar 17, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: To assess the long-term safety and tolerability in patients with cold agglutinin disease (CAD), after multiple doses of SAR445088 Secondary Objective: To assess, in patients with cold agglutinin disease (CAD), after multiple doses of SAR445088: * The long-term effect of SAR445088 on complement mediated hemolysis * The long-term pharmacodynamics (PD) effect of SAR445088 relating to complement inhibition * The long-term pharmacokinetic (PK) profile of SAR445088 * The long-term immunogenicity of SAR445088
Conditions
- Autoimmune Haemolytic Anaemia
Interventions
SAR445088Drug
Pharmaceutical form: solution for injection Route of administration: IV and SC (Part 1) IV (Part 2)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-emergent adverse events (TEAE)Time frame: Day 1 or Day 1-IV to end of study, approximately 6 years
Locations
5 sites in 5 countries. Site status is shown where the registry gives one.
Investigational Site Number : 2760001
Essen, Germany
Investigational Site Number : 3800001
Milan, Milano, Italy
Investigational Site Number : 5280001
Amsterdam, Netherlands
Investigational Site Number : 5780001
Bergen, Norway
Investigational Site Number : 8260001
London, London, City of, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.